- Earnings call transcript Q3 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and welcome to the Virios Therapeutics, Inc. Q3 Earnings Update. [Operator Instructions] It is now my pleasure to turn the proceedings over to Angela Walsh, SVP, Finance and Treasurer for Virios Therapeutics Inc. Angela the floor is yours.

Angela Walsh

Thank you. thank joining and conference on everyone, call. morning, you us for today's Good

start during website. to available today call trial that provide Greg press with will Therapeutics and are completed review then Please financial providing of quarter. be We our today's Gendreau, to pleased note our our with Duncan, return Mike from will you on as our of ongoing will on financial third I he is We'll recently release the as quarter the study. results Dr. over who you CEO on Xb on update third results, FORTRESS brief provide our results to study know well our summary as our with Officer, fibromyalgia update our financial a results. Phase our to now Chief analysis also turn quarter Virios Then discuss the analysis, a the call corporate Medical progress past an FORTRESS

Ralph our answer with and President for Vice call. us Grosswald, Senior of question is of Operations the the portion addition, In

these materially Before forward the of during involves statements will I'd call this the looking statements from or include uncertainties that of forward and by we risks statements. results that Litigation made differ conference information like actual to remind meaning Reform Securities to the begin, which Private within Act looking everyone XXXX, implied cause can expressed

our pleasure statements press Please forward turn looking Duncan. financial issued my of we the the morning any factors filings the statements now over information. these with It more by update only are forward-looking information risks see required company's statements today. the this looking CEO disclaim to For law. outlined SEC. our in Greg please And such section to uncertainties, as as more than for results call risk to regarding obligation other forward is release the and in Any see made

Greg Duncan

to three all us morning on good And Angela. of today's joining quarter update. earnings you, Thank you

today's Our discussion goals for are threefold.

line top learned in summary will far of you First, Xb provide following we FORTRESS have from with our September, the we results study data. mid so Fibromyalgia of our the a detailed examination, phase announcement what

the well diagnosis. of the this of XXXX Fibromyalgia and analysis associated were this into first the but phase enrollment unusual response of the will bifurcation as in demonstrated XXXX. on finally, our based of potential discussed milestones of achieve suggested trials infection reduction. that placed patient clearly September treat herpes significance IMC-X successful fatigue Xa pain symptoms Fibromyalgia outline was our tolerated, receive plan XX% the both line year provide proposed three safe opening call development when of preliminary that reported patients role background and a of FORTRESS endpoint we viewed timing early trial, data mechanistic FORTRESS we'll top our in from participants study of way context XXXX. up the June on November an by enrollment the of On our of to well to The to September, very confounded, results results as fibromyalgia, phase prior projected we IMC-X statistical did diagnosed with replicating not the highlighting IMC-X's mid pre-specified novel active particularly primary with approach and previously that quarter Xa questions. And financials the patients before a XX other the we In the Second, data a as trial. in and summary of pain, Recall demonstrated,

development most the and quarantining trial, treated were which vaccination quarantining full lessening probably the in of was COVID-XX today demonstrate with The of patients lifestyle. enrolled strain during across when of to April substantially from patients the Alternatively first trial, back the during here patients November highly the we importantly, was in second to COVID-XX totaled results. below respond which here patients FORTRESS most that a help of will significant both at impacts enrolled study, many year, The we're enjoyed XXXX the statistically variant deeper Virios design had with second half significant FORTRESS the geographies. the in substantial negative second place a or was our the a of data results. demonstrated when This past and the second on in the For statistically full the Conversely, vaccination rates was context, place final during positive response identified levels outcomes the in recruited a the pain one severe size stark spent The management factors half was the strain as program half this time day The management sample has believed essentially, to geographies is to the believed this that such patients removed timing the far team XX the well half be reduction in driving who getting In the during of extensive team period that several improved. the primary positive this, became we of an IMC-X deeply Virios placebo line day dominant half This to dominant study reduction top most we likelihood pain the a half team as team U.S. to we patients are fibromyalgia likely has IMC-X patients all week variant team demonstrated occurrence. weeks roughly analyzing patient differential the targets U.S. on and U.S. significant still stated, of demonstrate study was not unlikely Delta where took in the required endpoint compared treatment. fully in IMC-X the did few with FORTRESS normal believe less of that a to first to required restrictions improvement enrolled reduction a the treated the better the in into understand contrast enrollment symptoms. pain XX% patients were understanding same the as exploration. study statistically Omicron study. random factors and time on to had of period. improvements when treated the significant a rates more XXX statistically based trial the the fatigue and IMC-X of over

who results are unlikely multiple Fibromyalgia the plan to that study in corroborated potential support IMC-X positive these to treatment vetted we trial the supported have FORTRESS recognized for continue chance, highly diagnosed FORTRESS view with patients the experts findings the as We with IMC-X. our These fibromyalgia. that of development due observed the a our do proposed of thought and research leaders, results

will it to on Mike. We away, what will It underpins fibromyalgia. Mike the IMC-X that shortly share continued of to requesting we Chief propose of to can distinct FDA now to also thoughts IMC-X pleasure meeting to to turn the FDA with my Medical progressing Gendreau the the treatment over be three plan have discussion our advance will of broad share with that next the a forward. R. the year. Dr. goal we development learned parameters is Take Mike live development phase IMC-X Officer, our of improve belief our moving

Dr. Mike Gendreau

Thank you, morning. And good Greg.

that As trial. the to the and with Greg rate with in research, responses factors the weeks several research team spent the data the the respect prior has or led improvement referenced, goals understand the past demographics patient particularly detail Virios better were FORTRESS the consistent that of placebo not study, with design analyzing of to in to our

outstanding. all enrolled and with In and was that the April profile statistically size. trial post from half responses time November analysis hoc plan IMC-X of from patients improvements Greg to as subgroup half patients to of significant demonstrated in first mentioned, expected November XXXX the clinically sample and half the second the were original second points, IMC-X the the safety recruited Greg half of efficacy consistent the mentioned, tolerability However, April original with of at

have this at to and Our share efforts populations as responsive that that the with learned time, to what IMC-X summary to well you as been has more team factors a now better identifying the characteristics weeks the over were understanding last over to-date. response overall led pleased treatment. few of am a different directed achieving I research

impacting a careful you As analyzed original in understand FORTRESS and demographic shared the goal. September, differed full had why impact timing be that FORTRESS design manner might our of results imagine, in we results conducted to considering were subpopulations the of the understanding to enrollment back variables a from factors many the

So have learned following. far the we

research naive and significant new this the of FORTRESS were analysis that will for that timeframe. which Improvements studies, is patients call symptoms, we were symptoms. entire the or depression statistically in results observation population study post fibromyalgia clinical who clinically demonstrated statistically new in FM First fatigue, anxiety hoc and trial pain, indicate significant to reductions patients,

site will less to represent patients in database trial we contrast, refractory other study a who enrollment as call combination compared far care population enrolled either resistant participants benefit did meaningful subpopulations. this a to So treatment treatment in or study medical general patients, our not cohort as were communities. used exhibit as their for results the appear patients we've by impacted now in and experienced well In recruit who timing prior-Fibromyalgia provide more patients, of treatment clinical sites for patients that research patients both trials a they sites, and dedicated this of in Historically, timeframe. are and

sites results the clinical management to pandemic research compared that indicates better that turnover as response placebo delivered data to dedicated Our in consistent more were likely sites. staff practice clinical the the less including experience

forward to on a with moving sites. dedicated plan future execute Our research focus be IMC-X will trials

to associated FORTRESS had the While the clear successfully in to remains of we that environment extraordinary midst this the impacts study on trial circumstances overall it pleased results. our be pandemic, the unintended were FORTRESS recruit able with

community, time to patient presently United While expected they the now when free we targeting new response half observed patients we trials. those be research may patient demonstrated whereby has more they becoming more related as confident such expended the treated rates, and been study can't in. newer, the moving Fibromyalgia experienced that reaching guarantee will more in our States a treatment point for be a On note, of being trend research research we in response subjects depression, that may potential as drug rates given we're be conducted IMC-X's were be trial a COVID of patients represent several target other which optimal in in categories, characterized where lower and energy naive for must saturation forward, believe This treatment. who environment, future fibromyalgia irrespective placebo recruited recruit in refractory to

development time, this with factors we a impacting tolerated our could our highly on study forward available expect in subjects, there feature three is IMC-X that as material phase to a believe IMC-X evidenced as of a all on study many a by fully the Xa as other that important phase This be be never feature while dynamics we than lower by therapies. to factors that FORTRESS result successful, discontinuation was In trial the versus of results. plan conclude the COVID a that development. We very remember successful moving over with due differentiated likely IMC-X and are to It impact treatment supports will adverse placebo. rate to events is case, IMC-X had well we our summary, progression understand, if are was such impact of can there

with Importantly, believe many this better manage us these we future can will that design trials of understanding, factors. we help

results meeting into our We our review will with three shortly FDA a guidance plans phase advancing be and development. for requesting to IMC-X present full

forward meeting. safety excellent FDA profile phase propose any during I to this data be likely granting our about Hence, our the further to any and observed is feedback FDA our to happy further understand three XXXX. comprehensive FORTRESS, not of in plan that the that half development we FDA year. answer meetings Q&A We the plans we Given a would session. are live program analysis questions first receive to moving sometime obtained at in

quarter welcome Let Angela? Finance President our Senior Angela back me our and Vice of financials. discuss to Treasurer three Walsh

Angela Walsh

Thank you, Mike.

external to bifurcation of cash update be discussed FORTRESS our context, In data new quarter second we data to development IMC-X both top required the The following in decision data, September. forthcoming additional through capital our review capital company our raise provides with and This capital of plans on resources had consultancy in provides the during based that reporting discuss as engagement time We XXXX. aforementioned the greater get with operational to XX time, and proposed forecast in depth. allow the the also FTDs the us this FORTRESS the made approximately results months line do. runway the additional which of live upon company those As for to to earnings especially the the project discussions Albeit response most plan and to meetings, occur likely of will FDA. XXXX. workload, dependent timing requests will related current we at

As of XXXX, million in million to December September XXXX. $X.X XX, had as compared cash we of as $XX XX,

the expenses of the the $X.X decrease XXXX we and through loss of as our ago require to sufficient XXXX. and of $X.X $X.X generate in months was million year current future million the quarter-over-quarter clinical studies three the in note XXXX I net lower just capital. not stage million million year third ago our related A $X.X the for in expect due to Toxicology statement months quarter-over-quarter million, September the and drug and as development three quarter. of primarily income a million phase for the three the for XX, a was to quarter for We related And research million. our respect reported to expenses in $X.X We FORTRESS net quarter costs operations a end cash of quarter decrease XX, and development quarter. manufacturing net of lower during general but in to a salaries our ended mentioned. reported including be that the $X.X development for a for a $X.X A as expenses compared ended costs. loss during biotechnology related expenses was expenses XXXX or to September Program study XXXX a and revenue to decrease company, million and decrease costs trial IMC-X to of will third research due any A XXXX compared chronic we September primarily With as $X.X year development fund of $X.X third administrative research finally, of the reported We ago XX, did million to loss quarter. for of primarily to ended company's decrease additional development decrease compared development

and up the Let Duncan me back moderate the answer call. Greg and of discussion portion turn Greg? to wrap to the question

Greg Duncan

alignment will believe over in covered FORTRESS This coming are Angela. us extensive FORTRESS three FDA is analysis again, which the first next proposed a with key the program by insights data our to these in The likely to with factors to subject and insights recent half research study patients analysis hope recruiting enable We We reach approach to irrespective related conducted from fibromyalgia second external to treatment once and additional of in phase data trials. research new program emphasis by the the who of design out patients Thanks the our of availability to Mike team discussed commence phase be FDA IMC-X XXXX, of of several previously patients failure, screening most This including IMC-X or dynamics. supported research, fibromyalgia for months. respond has on into gleaned been FDA study. includes have live the patients to of clinical a COVID to participated fibromyalgia of with with half history the XXXX. engagement,

of operations research and/or capital Angela support. future until remarks, partnership require have will in her But to end referenced we support As XXXX. capital the additional

we prospective funding to engaging partners optimal for the and current forward commence with executing development. new will with path also and discussions the In IMC-X determine investors both FDA, and addition to

patients remains ultimate to with same. Our care we hundreds enhance fibromyalgia of not Operator, millions IAMC-X goal the Getting presently for now for to standard of satisfied treatment options. current market ready the are questions. of

Operator

[Operator now ahead. from Wainwright. for is Sir please Instructions] Lee open H.C. floor Thank you The gentleman. with is questions. first question ladies Our Sean and go coming

Sean Lee

rationale my morning, the on better drugs a better guys. have the that patients? of action good could like questions. get what would of for Good the rate new patients you explain than of it experienced analysis. some the understand the thanks And some why taking mechanism response to behind the based would is fibromyalgia I And

Greg Duncan

is me Greg Sean, let Duncan, this Hey, that take one.

and is to been of had the So whole a this mechanism. of as the comments, may is There group. novelty And as reason actually seen that with clear more other patients a cause why in just group act that in his as was our which where group, to replicating leaders we're and other may validated treatment that is population. fundamentally of why saw in point is which trial. by the as new we've have virus treating refractory responded treatment today. new treated you group, or But population, trials know, be a as earlier well majority would key was fact naive ethos may represent spoke not depression guess. of the previously patients to they the we and/or happened, been because clear to, represent have why in not consistent Mike patients root and into of as get some participants, by in new those we experienced a naive program why patient had participants is trying a prior that experienced that a that participating what responded, the recruited It a for point program we candidates have both we approach the a the that patients. hitting the were patients therapies, refractory fibromyalgia mentioned trial most that as that refractory reviewed and just that's in more in opinion have may not represent to fact that second a don't other may in be the we those of discussing those three as than that a potential as other to We really view or We data potential don't hitting trial We areas. tipping that

it's nature I a refractory just patients. general overall So of suspect the

Sean Lee

for I Thanks that. see.

fibromyalgia, classification in any studying In of the or standard experienced of been classification these patients using a has do for terms whether clinical whether this setting? you new other that's patients classification or

Greg Duncan

distant we So why not were patients that that new had were who clinical were advertising. the nor the definition, the a patients the particularly group patients define by in clinical purely through while because trial as were And may is participants I referenced past. were These way on a have participants, lists. used, physicians that research trial second in in sometime recruited trial, not the patient patients we patients prior that those in the centers participated they were likely identified will recently in

exhaust clinical have so it sure prior trials We to this treated. these tried we were But to a been The And in clinical depression relatively patients, get in going patients may way that trials. the patients newer They you manageable. little are clinical particular mechanism. make the this list, goal bit kind participants. sites, then you back were you in move run use not to day. of we excuse not patient been previously pool, but out your previously do the all is not patient forward did you Those who analysis, they true recruiting in let's you've know and is me, that find, harder newer trial in say, off and you be prior that the okay, that trials, will go

clinical to those differential patients. that through three, here them only consider get phase U.S. launch. We other You makes screening sense new markets, can anyway, we moving consider IMC-X the research because in some you use to so saturate can precursor think other also with experience which that's actually we to as to as really going a requirements starting recruit geographies,

based we just think exactly through do So wise to screening share the with manageable it's we we way better it's today. data and you the go on think here

Sean Lee

My last study. see. three on is I potential question phase

terms expect you in geographies. the mentioned and can So be FDA? like we of would what size, What around the proposing to what then you

Greg Duncan

feedback recommendation, So the we're to FDA regulation. one following. which will the process trial, our is do include an will likely that Again, general multifactorial in finalizing but of approach subject FDA

there's But will So famciclovir. include to We that's arms, famciclovir may probably reason independent IMC-X argue and have probably one one as two placebo, a components. on celecoxib can that. view different FDA no certainly test

four study. that think a three So as or probably arm of

two we do be make head label third IMC-X the proposing the of one component that part back overall would the to should the are required case be may, package and clean will will program FDA if head you then may NDA continue That successful. be to head head And come as We a to of may the a two to we that would second that do and we trials. be extension again open trial, multifactorial of placebo. we like to say that arm support key an an data to eventual safety

label multifactorial with and extension. So feedback, open head three Hopefully depending the studies. on an to head it it's two and be may that probably caveat one FDA multifactorial one

part the some three effects, trials three. phase be probably there kind etc So that are will of and food particular standard other classic then trials of of

Sean Lee

for additional for That's questions I the again And have. all Thanks the questions. thanks color. my taking

Greg Duncan

participating Sean. Thank questions. Appreciate you the for

Operator

coming Please is with next Bautz Instructions] from David [Operator question ahead. Our go Zacks.

Unidentified Analyst

me, Hey, excuse it's Actually, you? David. Hi, calling are for Greg. Richard how [indiscernible] Angela,

Greg Duncan

morning. Richard. Hi, Good

Unidentified Analyst

David, Good just shortly. the going sure call up to He on be morning. couldn't Yes, I'm this morning. follow he's

he to guys. So a me questions gave ask you few

with trial IMC-X that. things like the happened and I about think and very been clear you've what FORTRESS

in into to going new encouraging, it's little to think patients. phase sure deeper, dig a with but I'm want bit three it he'll take you're and FM So I dive the

give I'm it you and Maybe, any great. that's you've sure more that. So given can't I'm sure a than timeline,

then hopefully, to a and the approval if of year, year, meeting year, first first FDA, and understand into you next live half be then and as hopefully next of it's next the So going funding correctly, the going to then shortly in half be required. three, getting understood additional second there's moving interim, phase with half of I it, I

the And give what would is it? whole range So would the you delay simply, question of that that can that funding my factors required? a What the are process? on are kind accelerate factors

Greg Duncan

Okay, thank you, Richard. there. There's in a lot

that. So try address one, subject go three, goal be that's feedback. to to me let would our FDA to Number obviously to phase

based interaction now scheduled of important on point. It of consultants, FDA that it's of we in is balance three. to understanding, targeting are think our goal. that intelligence last quarter progressing data, I that best think the safety our our for live being in one. mention the year. sometime the to population, that this not the is is efficacy regulatory meetings one So phase We to this with totality timeline data quarter end can't are but at this requests guess They guarantee our our that you the data, we support The gave middle the

So we that feedback the The sometime for guess and live program research half to right now XXXX. best here external but point. that an you that goal the FDA is can feedback. clean this we second could we in obviously needless then the to days our recruitment guess out has that for in The completeness, would to to to be entity. report at give would that be meeting, say, have in have we if And goal good successful we're our formal hope be, as Probably, those community which sites. is commence discussions, the relationships with of that XX best

financing, ready we go nurture to feedback. an that to and relationships so to continue funding, will We FDA those are subject etc,

So the of to in be the very etc, possible. such at experience one a on as Mike, point of soon this the Ralph, would required benefits guess. best is good start as the guess sites relationships, capital general that team The we some with having that's have space

bit partner, $XX be the in operations. $XX million as finding of too for but lesser plus talking feedback. probably estimate to this range what to amount, point, three successful think we it's at phase a early to phase are You're it's in FDA subject may program a and a get I the because three probably million If would an in cost little to totality refined that

Unidentified Analyst

it. Got

Okay. for that. Thank you

to Have FM? a Just over questions. that. more David we you IMC-X. haven't over to to testing to IMC-X, Is switch ever in considered? that's been considered about something couple switch that talked wanted IMC-X I want ever

Greg Duncan

trial. So, may we famciclovir me do for just of as to celecoxib data IMC-X you let the the IMC-X combination celecoxib. is is the a progression IMC-X support back completeness really COVID and so selected think and IMC-X know up for combination We valacyclovir of celecoxib. IMC-X phase long three. and valacyclovir

bad end That's results the trial. actor, activation herpes of For epstein the recruitment on one first conducting think trial, bit out test. COVID the it's this program report the valacyclovir supported half on the year. with investigational sometime the That's associated and bone reason fatigue, the of who data the barr, the that's reason, in of secondary epstein finish to Center And hope is etc. we bad actor brain by that's which which which the leading Bateman plus we one only little a next is fog, barr, viruses, the more year Horne is through selective that based including our a That's perusal to of in grant sequelae. the celecoxib to

viruses. the that of here timeline to long them herpes So very we and the Famciclovir talk timelines the we for do program. is COVID the think guarantee frequently but good rough number has can't activity against

know manufacture to how great relatively formulation efficiently. have it we We

we'll and move forward of fibromyalgia for And so with long pending with IMC-X the do results be the goal program. would COVID to what explore to the IMC-X

Unidentified Analyst

David Is Okay, mentioned you winning what backburner. an so had IBS Is focused you're that I'm that the and just was something put because to referring that were is on IMC-X? clear else? program with on COVID

Greg Duncan

treats believe patients this we Dr. The disorders. disorders also somatic things Pridgen different of like syndrome was original IBS, number was for actually and IBS William utility his has perform surgeon. an utilization treats in do So, of across mechanism He like founder, at a functional GI population. this potential but patients surgery, gastric combination

He a open So saw and that a gut diagnosis they fibromyalgia, were a of biopsied follow really where patients there fantastic care, virologist actually had Dr. form patients demonstrated and who their of has prior he if active the patients And tissue. were infection who they label patients. describe program, of very fibromyalgia Duffy Carol a what gut connected executed for for to replicating These patient, GI results. up control tissue or functional the other novel up, that control maybe with University will, in who herpes follow GI had you very a disorders, with good a I of results, them with as compared that clearly patients diagnosis of are would at bleed, Alabama. some

What we study who And third also the corroborates of which purely activated of in GI was patients that portion so a activity herpes presented functional were the was of there patients. believe fibromyalgia data virus had is part disorders. as those

Duffy at tissue breaker infection highly The breaker. believe. important And that it presentation significant year, by data dominant presented just I statistically poster fibromyalgia, he was sorry IBS category active disorders, Dr. digestive was there. disease is level. week last analysis. noted at replicating so year, in was And The elite actually those were So elite this functional meeting the including those patients trial GI no their gut in probably also the a

right is the as a a a IBS subject we IBS. time, in certainly do IBS But connection priority That long one, over So is pipeline feedback, an IMC-X. if potential is fibromyalgia. the to into for in we That's potential etc. presuming we program complement have virus herpes expand execute obviously is, and we COVID priority think funding, the research between safety community success can there's there did the that program, news think on the third a extensive data support, good now two, program now we priority. community and The FDA interested fibromyalgia are as to activation

good. very tolerability As you safety earlier, know, Mike mentioned IMC-X the of and is

the hand. of be particular data forward safety FDA line dialogue of with if we the And in those so would that part research decided that pursue to data with important safety moving an

So do an is that Pridgen’s Dr. we biopsy exciting on now. based third priority experience priority the is study. it But in our right think GI

Unidentified Analyst

sure Greg. I for follow be that, contact David in and up mentioned, things Well, And, thank shortly Excellent. to I'm as will Excellent. you like that.

good encouraging luck. ones. It's move with anyway, three So patients guys new with you into new phase to

your So to that's thank great. and We're looking XXXX you time. for forward

Greg Duncan

Yes, thank you, Richard.

new overall and improvement IMC-X and in reaching be global fibromyalgia symptoms were point trials much overall fatigue, patients in three. a ideally patients that are may We are health. goal improvement to patient's that benefits clinical data IMC-X to target an the We IMC-X of believe that to of fibromyalgia demonstration summary are research saturation pain based more fortress reduction phase certainly patients take those progression do phase that reveal for development on including representing that to refractory excellent reduction significant an in in is Our three, in where population. the prior

a the consecutive attention We that do recall, IMC-X reason and adverse poor the believe tolerability story medications. dissatisfaction little is as reduce They take existing will before rate the that if is patients But that trial primary And actionable than the is the the you heard of it community due less those time leads compliance. for to you've bit compared patient lower more are probably treat to clearly pain. where the dropout amongst those second to fibromyalgia issue forward it good They continued ideal moving data but medications. impress. in patients pre-approved tolerability placebo. for the that all a doctors had development. very events doable and those target certainly safety This is with to as IMC-X and continued So

likely dosing advance to program as As is quarter on to I And to results the I to the totality whole as key Mike by of concludes you team this external Thank And will Thank regards year what mentioned the Full your progression communicate well, that time community call. the you during FDA our to Angela, FDA three. to recruit. safety data moving half will at with the the all the feedback mentioned conclude three to for first frequent then report immediately end program we communication Richard's question, phase development of will phase of and next for requesting be following our to And progression long continues earlier, you. earnings we COVID committed XXXX. enrollment operational Ralph, We milestone. this And that data myself, fibromyalgia. the the can accurate and hope shortly with that update. our next in be FDA see, forward steps today's the IMC-X's to phase three, support as are attention specifically, three. And and IMC-X's is Mike believe progress. back mentioned goal, COVID meeting and time. do we we'll really along going endorse to

Operator

gentlemen. does you Thank call. and ladies This today's conclude

your thank a your this you have day lines time at we may for You and wonderful participation. disconnect and

Dogwood Therapeutics (DWTX) 14 Nov 222022 Q3 Earnings call transcript